Published in Br J Cancer on January 01, 1991
Activity of boanmycin against colorectal cancer. World J Gastroenterol (2001) 0.85
Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice. Drug Metab Lett (2011) 0.75
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst (1988) 3.09
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep (1986) 1.61
A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst (1986) 1.49
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 1.49
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer (1987) 1.47
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs (1986) 1.41
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol (1987) 1.33
Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst (1989) 1.31
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst (1988) 1.26
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol (1987) 1.20
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res (1988) 1.18
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol (1988) 1.15
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta. J Natl Cancer Inst (1988) 1.12
Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treat Rep (1986) 1.09
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer (1989) 1.08
A comparative morphological study of the mammary gland in a high and a low tumor strain of mice. Am J Pathol (1938) 1.02
Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol (1989) 0.98
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer (1988) 0.97
Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res (1989) 0.90
Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro. Cancer Chemother Pharmacol (1989) 0.90
Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemother Pharmacol (1988) 0.88
Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512). Br J Cancer (1988) 0.81
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol (2007) 1.98
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Cowden syndrome. Cancer Treat Rev (2010) 1.80
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol (1998) 1.53
Role of surgery in patients with primary non-Hodgkin's lymphoma of the stomach: an old problem revisited. Br J Surg (1993) 1.46
A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol (1992) 1.42
Occult breast lesions: A comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL). Breast (2005) 1.41
Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol (2005) 1.39
Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta (1972) 1.34
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta (1992) 1.29
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res (1992) 1.29
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry (1990) 1.20
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate (2001) 1.18
The interaction of adriamycin and its beta anomer with DNA. Biochim Biophys Acta (1977) 1.16
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol (1998) 1.15
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets (2003) 1.12
Radio-guided localization of clinically occult breast lesions (ROLL): a DGH experience. Clin Radiol (2005) 1.11
Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet (1987) 1.08
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones. J Med Chem (1991) 1.06
Emergency liver resection for ruptured hepatocellular carcinoma complicating cirrhosis. Hepatogastroenterology (1999) 1.06
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res (2000) 1.06
Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol (2006) 1.04
Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis (1993) 1.03
A clinicopathologic study of primary hepatic carcinoid tumors. Cancer (1990) 1.02
An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res (1989) 1.02
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem (2001) 1.01
Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells. Int J Cancer (1986) 1.01
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta (1995) 1.00
Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Mol Pharmacol (1996) 0.99
Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol (1993) 0.99
A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer (2001) 0.98
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol (1999) 0.96
A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer (1999) 0.96
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene (1992) 0.96
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res (2001) 0.96
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer (1996) 0.96
Elective sigmoid colectomy for diverticular disease. Laparoscopic vs open surgery: a systematic review. Colorectal Dis (2012) 0.95
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res (2001) 0.95
ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem (2009) 0.95
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer (1996) 0.95
Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status. J Cell Sci (2000) 0.95
DNA topoisomerase-trapping antitumour drugs. Eur J Cancer (1992) 0.94
Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol (1971) 0.94
Mechanisms of cellular resistance to camptothecins. Curr Med Chem (2006) 0.94
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori (1989) 0.93
Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res (1986) 0.93
Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma. Eur J Surg Oncol (2000) 0.93
MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer (1995) 0.92
Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis (1997) 0.92
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res (1999) 0.92
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer (2004) 0.92
Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer (1990) 0.92
Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem (1999) 0.92
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem (2001) 0.92
Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res (2000) 0.91
Adrenalectomy for isolated adrenal metastases from non-adrenal cancer. Int J Oncol (2000) 0.91
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res (2013) 0.91
Specific inhibition of DNA-polymerases from RNA tumor viruses by some new daunomycin derivatives. FEBS Lett (1972) 0.91
Global gene expression of fission yeast in response to cisplatin. Cell Mol Life Sci (2004) 0.91
Surgical outcomes for colorectal cancer patients including the elderly. Hepatogastroenterology (2001) 0.90
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst (1997) 0.90
Endogenous oxidative stress induces distinct redox forms of tumor necrosis factor receptor-1 in melanoma cells. Ann N Y Acad Sci (2004) 0.90
The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer (2001) 0.90
New developments in antitumor anthracyclines. Pharmacol Ther (1998) 0.89
The interaction of daunorubicin and doxorubicin with DNA and chromatin. Biochim Biophys Acta (1980) 0.89
Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: sequence specificity and structural drug determinants. Cancer Res (1997) 0.89
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol (1998) 0.89
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol (1988) 0.89
Undergraduate training in oncology: an ESO continuing challenge for medical students. Surg Oncol (2010) 0.89
Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem Biol Interact (1977) 0.88
Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol (1997) 0.88
The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J Inorg Biochem (1999) 0.88
Validation of the modified TNM-Izumi classification for hepatocellular carcinoma. Tumori (2000) 0.88
Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers. Eur J Cancer Clin Oncol (1984) 0.88
Human tumor xenografts in nude mice are not always of human origin. A warning signal. Cancer (1999) 0.88
Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol (1994) 0.88
Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs (1994) 0.87
Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci (2003) 0.87
International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat (2013) 0.87
Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry (1993) 0.87
Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes. Int J Cancer (1994) 0.87
Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori (2002) 0.87
Molecular structural effects involved in the interaction of anthracyclines with DNA. Chem Biol Interact (1979) 0.87
Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ (2002) 0.86
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol (2013) 0.86